| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated) |
|
Medicine details |
|
| Medicine name | isatuximab (Sarclisa®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 4027 |
| Indication | In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Company | Sanofi |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/06/2021 |
| NICE guidance | |